Related references
Note: Only part of the references are listed.HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability
Gi-Ae Kim et al.
GUT (2014)
Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: A randomised open-label trial (OSST trial)
Qin Ning et al.
JOURNAL OF HEPATOLOGY (2014)
Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis
Roeland Zoutendijk et al.
GUT (2013)
Off-Therapy Durability of Response to Entecavir Therapy in Hepatitis B e Antigen-Negative Chronic Hepatitis B Patients
Wen-Juei Jeng et al.
HEPATOLOGY (2013)
Relapse of Chronic Hepatitis B After Discontinuation of Nucleos(t)ide Analogs: Is the Glass Half Full or Half Empty?
Jurrien G. P. Reijnders et al.
HEPATOLOGY (2013)
Long-Term Entecavir Treatment Reduces Hepatocellular Carcinoma Incidence in Patients With Hepatitis B Virus Infection
Tetsuya Hosaka et al.
HEPATOLOGY (2013)
Response-Guided Peginterferon Therapy in Hepatitis B e Antigen-Positive Chronic Hepatitis B Using Serum Hepatitis B Surface Antigen Levels
Milan J. Sonneveld et al.
HEPATOLOGY (2013)
Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype
Milan J. Sonneveld et al.
ANTIVIRAL THERAPY (2012)
Pegylated interferon results in higher serological, but not virological, response rates when compared to continuous entecavir
Milan J. Sonneveld et al.
ANTIVIRAL THERAPY (2012)
Restored Function of HBV-Specific T Cells After Long-term Effective Therapy With Nucleos(t)ide Analogues
Carolina Boni et al.
GASTROENTEROLOGY (2012)
High Frequency of Recurrent Viremia After Hepatitis B e Antigen Seroconversion and Consolidation Therapy
Kevin T. Chaung et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2012)
Young Chronic Hepatitis B Patients With Nucleos(t)ide Analogue-induced Hepatitis B e Antigen Seroconversion Have a Higher Risk of HBV Reactivation
Tai-Chung Tseng et al.
JOURNAL OF INFECTIOUS DISEASES (2012)
Shorter Durations and Lower Doses of Peginterferon alfa-2a Are Associated with Inferior Hepatitis B e Antigen Seroconversion Rates in Hepatitis B Virus Genotypes B or C
Y. -F. Liaw et al.
HEPATOLOGY (2011)
Viral load reduction improves activation and function of natural killer cells in patients with chronic hepatitis B
Eric T. T. L. Tjwa et al.
JOURNAL OF HEPATOLOGY (2011)
The Hepatitis B e antigen (HBeAg) targets and suppresses activation of the Toll-like receptor signaling pathway
Tali Lang et al.
JOURNAL OF HEPATOLOGY (2011)
Serum HBsAg Decline During Long-term Potent Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B and Prediction of HBsAg Loss
Roeland Zoutendijk et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
Nucleos(t)ide Analogues Only Induce Temporary Hepatitis B e Antigen Seroconversion in Most Patients With Chronic Hepatitis B
Jurrien G. P. Reijnders et al.
GASTROENTEROLOGY (2010)
Lamivudine Maintenance Beyond One Year After HBeAg Seroconversion Is a Major Factor for Sustained Virologic Response in HBeAg-Positive Chronic Hepatitis B
Hyun Woong Lee et al.
HEPATOLOGY (2010)
Entecavir Treatment for up to 5 Years in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B
Ting-Tsung Chang et al.
HEPATOLOGY (2010)
Long-Term Entecavir Therapy Results in the Reversal of Fibrosis/Cirrhosis and Continued Histological Improvement in Patients with Chronic Hepatitis B
Ting-Tsung Chang et al.
HEPATOLOGY (2010)
Hepatitis B Virus Resistance to Nucleos(t)ide Analogues
Fabien Zoulim et al.
GASTROENTEROLOGY (2009)
Chronic Hepatitis B: Update 2009
Anna S. F. Lok et al.
HEPATOLOGY (2009)
High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: A long-term follow-up study
Rami Moucari et al.
JOURNAL OF HEPATOLOGY (2009)
Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon α-2b
Erik H. C. J. Buster et al.
GASTROENTEROLOGY (2008)
Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B
Karsten Wursthorn et al.
HEPATOLOGY (2006)
Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B
GKK Lau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
A randomized, controlled trial of combination therapy for chronic hepatitis B:: Comparing pegylated interferon-α2b and lamivudine with lamivudine alone
HLY Chan et al.
ANNALS OF INTERNAL MEDICINE (2005)
Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised
HLA Janssen et al.
LANCET (2005)
Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B
M van Zonneveld et al.
HEPATOLOGY (2004)
Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy
B Werle-Lapostolle et al.
GASTROENTEROLOGY (2004)
Share Paper
